# Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC

> **NCT07392073** · — · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 80 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Lung Adenocarcinoma
- Lung Squamous Cell Carcinoma
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)

## Key facts

- **NCT ID:** NCT07392073
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-04
- **Final completion:** 2029-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392073, "Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC". Retrieved via AI Analytics 2026-09-05 from https://api.ai-analytics.org/clinical/NCT07392073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*